These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29436397)

  • 41. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opiate use disorders and overdose: Medical students' experiences, satisfaction with learning, and attitudes toward community naloxone provision.
    Tobin H; Klimas J; Barry T; Egan M; Bury G
    Addict Behav; 2018 Nov; 86():61-65. PubMed ID: 29198489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Do heroin overdose patients require observation after receiving naloxone?
    Willman MW; Liss DB; Schwarz ES; Mullins ME
    Clin Toxicol (Phila); 2017 Feb; 55(2):81-87. PubMed ID: 27849133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is systematic training in opioid overdose prevention effective?
    Espelt A; Bosque-Prous M; Folch C; Sarasa-Renedo A; Majó X; Casabona J; Brugal MT;
    PLoS One; 2017; 12(10):e0186833. PubMed ID: 29088247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths.
    Strang J
    Addiction; 2015 Jul; 110 Suppl 2():27-35. PubMed ID: 26042565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heroin and pharmaceutical opioid overdose events: Emergency medical response characteristics.
    Banta-Green CJ; Coffin PO; Schoeppe JA; Merrill JO; Whiteside LK; Ebersol AK
    Drug Alcohol Depend; 2017 Sep; 178():1-6. PubMed ID: 28623805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Take-Home Naloxone and the Need for a Publicly Funded Naloxone Supply.
    Kim HS; Aks SE
    J Addict Med; 2022 Jan-Feb 01; 16(1):1-3. PubMed ID: 33534277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid overdose prevention training with naloxone, an adjunct to basic life support training for first-year medical students.
    Berland N; Fox A; Tofighi B; Hanley K
    Subst Abus; 2017; 38(2):123-128. PubMed ID: 28027016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.
    Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
    J Urban Health; 2016 Feb; 93(1):117-30. PubMed ID: 26800987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of lower-dose versus higher-dose intravenous naloxone on time to recurrence of opioid toxicity in the emergency department.
    Wong F; Edwards CJ; Jarrell DH; Patanwala AE
    Clin Toxicol (Phila); 2019 Jan; 57(1):19-24. PubMed ID: 30032680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Process evaluation of the Prevent Overdose in Toronto (POINT) program.
    Leece P; Gassanov M; Hopkins S; Marshall C; Millson P; Shahin R
    Can J Public Health; 2016 Oct; 107(3):e224-e230. PubMed ID: 27763835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized controlled trial of a computerized opioid overdose education intervention.
    Dunn KE; Yepez-Laubach C; Nuzzo PA; Fingerhood M; Kelly A; Berman S; Bigelow GE
    Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S39-S47. PubMed ID: 28363318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incorporation of poison center services in a state-wide overdose education and naloxone distribution program.
    Doyon S; Benton C; Anderson BA; Baier M; Haas E; Hadley L; Maehr J; Rebbert-Franklin K; Olsen Y; Welsh C
    Am J Addict; 2016 Jun; 25(4):301-6. PubMed ID: 27219823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of a Modified Community Trailer to Manage Patients with Presumed Fentanyl Overdose.
    Scheuermeyer FX; Grafstein E; Buxton J; Ahamad K; Lysyshyn M; DeVlaming S; Prinsloo G; Van Veen C; Kestler A; Gustafson R
    J Urban Health; 2019 Feb; 96(1):21-26. PubMed ID: 30324356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana.
    Ray BR; Lowder EM; Kivisto AJ; Phalen P; Gil H
    Addiction; 2018 Dec; 113(12):2271-2279. PubMed ID: 30255531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics of Patients With Opioid Use Disorder Associated With Performing Overdose Reversals in the Community: An Opioid Treatment Program Analysis.
    Katzman JG; Greenberg NH; Takeda MY; Moya Balasch M
    J Addict Med; 2019; 13(2):131-138. PubMed ID: 30303890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment.
    Drainoni ML; Koppelman EA; Feldman JA; Walley AY; Mitchell PM; Ellison J; Bernstein E
    BMC Res Notes; 2016 Oct; 9(1):465. PubMed ID: 27756427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program.
    Katzman JG; Takeda MY; Greenberg N; Moya Balasch M; Alchbli A; Katzman WG; Salvador JG; Bhatt SR
    JAMA Netw Open; 2020 Feb; 3(2):e200117. PubMed ID: 32101312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.
    Kerensky T; Walley AY
    Addict Sci Clin Pract; 2017 Jan; 12(1):4. PubMed ID: 28061909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.